{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.
Hangzhou Tian-Mu-Shan Stock Soars 7.66%, Hits Intraday High of CNY 22.75
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. saw a notable increase in stock performance on March 27, 2026, reaching an intraday high. The company has demonstrated strong annual gains, significantly outpacing the China Shanghai Composite, but faces challenges with modest sales growth and a high debt-to-equity ratio.
Hangzhou Tian-Mu-Shan Pharmaceutical Hits Day Low Amid Price Pressure at CNY 19.10
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. saw a notable decline in its stock price, reaching an intraday low. Despite a year-to-date increase and strong annual growth, the company faces challenges with its long-term fundamentals, including a modest Return on Capital Employed and a high Debt to Equity ratio.
Hangzhou Tian-Mu-Shan Stock Hits Day High with 11.69% Surge
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. has seen remarkable stock performance, with a significant increase on February 24, 2026. Over the past year, the stock has risen substantially, outperforming the China Shanghai Composite. However, the company faces challenges with its long-term fundamentals and high debt levels.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
